Neurizon Therapeutics Limited has released a press release.
PAA completes Phase 1 and files for Orphan Drug Designation
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Prospectus & Target Market Determination
- Appendix 4C and Quarterly Update
- Options Offer to Existing Listed Option Holders
- Final MND Patient in Cohort 4 Successfully Completes Dosing
- Canine Oncology Data Supports Progression to Registration
Later from Neurizon Therapeutics
- PharmAust Raises $3.5 Million at a Premium
- 93% take up in Options Offer
- PharmAust Receives R&D Tax Incentive Refund
- FightMND Invites PharmAust to Apply for Phase 2/3 Funding
- FDA Grants PharmAust Pre-IND Meeting
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics